Testing LW402 tablets for non-segmental vitiligo
Part of Skin clinical trials.
This study tests whether a new tablet called LW402 can help restore skin color in people with non-segmental vitiligo (white patches that spread unpredictably across the body). The medication works by targeting immune cells that attack skin pigment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have non-segmental vitiligo (the type where white patches appear randomly, not in one stripe or area)
- White patches cover at least a small area of your face and at least 3% of your total body
- Your vitiligo is either getting worse or has stayed the same (not improving on its own)
- You have not had an allergic reaction to JAK inhibitors (a class of immune-suppressing drugs)
- Less than one-third of your white patches are pure white hair, and patches are not limited to hairless areas like lips or palms
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called LY4005130 for non-segmental vitiligo, a skin condition where patches lose pigment (color). The trial aims to see if this drug can help restore skin color and stop the spread of white patches.
This Phase 2 trial tests whether a new drug called D-2570 can help restore skin color in people with non-segmental vitiligo (when white patches appear randomly across the body). The study will track how well the drug works and check if it's safe to use.
This trial tests a cream (ruxolitinib) combined with corticosteroid treatment for people with active, non-segmental vitiligo that affects the face. It aims to see how well this combination works in real-world settings.
This trial tests a new oral medication called ACT-777991 to see if it is safe and can help repigment skin in adults with non-segmental vitiligo (the most common type that affects both sides of the body). Participants must have at least a certain amount of pigment loss on the face and total body, and agree not to use other vitiligo treatments during the study.
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
This study tests a new medicine called FB102 for people with non-segmental vitiligo. It aims to see if the drug is safe and helps restore skin color.
Hear when a new Non-Segmental Vitiligo (NSV) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.